Related Experiment Videos
Prolonged bleeding time in preterm infants receiving indomethacin for patent ductus arteriosus
Insights
Indomethacin treatment for patent ductus arteriosus in preterm infants prolonged bleeding times, but major bleeding complications were rare. Platelet dysfunction did not significantly increase hemorrhage risk in most infants.
Area of Science:
- Neonatal Medicine
- Pediatric Pharmacology
- Hematology
Background:
- Patent ductus arteriosus (PDA) is common in preterm infants.
- Indomethacin is a common treatment for PDA.
- Indomethacin can affect platelet function and potentially increase bleeding risk.
Purpose of the Study:
- To evaluate the effect of intravenous indomethacin on bleeding times in preterm infants with PDA.
- To assess the association between indomethacin-induced platelet dysfunction and hemorrhagic complications.
Main Methods:
- Sequential bleeding times were measured in 25 preterm infants before and during indomethacin therapy.
- Clinical bleeding and intraventricular hemorrhage (IVH) were monitored.
- Bleeding times were correlated with IVH extension and other clinical factors.
Main Results:
- Indomethacin administration significantly prolonged bleeding times, which remained elevated for at least 48 hours post-therapy.
- Clinical bleeding was infrequent and mostly limited to occult hematuria.
- No clear link was found between indomethacin, bleeding time prolongation, and IVH extension.
Conclusions:
- Indomethacin-induced platelet dysfunction in preterm infants with PDA is generally not associated with major bleeding complications.
- Other factors, not indomethacin-induced bleeding, appear more critical in predicting IVH extension.
Abstract:
Sequential bleeding times were performed on 25 preterm infants receiving intravenous indomethacin for closure of the patent ductus arteriosus. Prolongation of bleeding time was observed after the initial dose of indomethacin, with an increase from a pretreatment mean of 3.6 minutes to 8.7 minutes. The bleeding time was not further prolonged at the end of the three-dose course of indomethacin, but was still elevated 48 hours after the completion of therapy. Clinical bleeding developed in six of the patients, but was generally limited to occult hematuria. Serial echoencephalography during indomethacin therapy showed progression from mild periventricular-intraventricular hemorrhage to moderate or severe grades in five of 21 infants at risk for this complication. However, no clear temporal relationship between indomethacin administration and intraventricular hemorrhage extension was observed, and no difference in the degree of bleeding time prolongation was noted between infants with and without hemorrhage extension. Other factors, including surfactant deficiency, amount of volume expansion used, and lowest PO2 in the first day of life, did distinguish those with hemorrhage extension. The results suggest that indomethacin-induced platelet dysfunction is not associated with major hemorrhagic complications in the majority of preterm infants with patent ductus arteriosus.